drugset / Trial / NCT01423656

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

NCT01423656

Phase 1 Completed 102 enrolled LEO Pharma
RandomizedParallel-groupSingle-blindOther

Summary

The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects. The study is divided into one single dose part, one part to compare pharmacokinetics between gender and one multiple dose part.

Timeline

Start
2011-08
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 29102 Unknown Other

Indications